Kate Yen is the Founder and CEO of Auron Therapeutics, a biotech leveraging cutting-edge science and AI-powered analysis to develop next-generation cancer therapies by mapping key drivers of tumorigenesis.
Kate earned her Ph.D. in Biological Chemistry from UCLA, where she also completed her postdoc. She held roles at Merck and as a UCLA professor before joining Agios Pharmaceuticals, where she led the IDH translational research team behind two FDA-approved IDH mutant inhibitors and co-led the discovery of vorasidenib, a promising glioma therapy now in clinical development.
Get the latest from The Biotech Startups Podcast delivered straight to your inbox. Subscribe for weekly updates on new episodes—featuring expert insights, actionable advice, and stories from across the biotech industry.
.png)